Global R&D Pipeline
My Favorite
Hot Targets:
α-SYN
Back
Total number of drugs
174
Phase II and later clinical stages
6.3%
Involving companies
214
Main therapeutic areas
Nervous System Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABL-301 | ABL-301 | Bispecific antibody | Nervous System Diseases Endocrinology and Metabolic Disease | IGF-1R antagonists α-synuclein inhibitors | ABL Bio, Inc. | ABL Bio, Inc. Sanofi | Phase 1 | - | - | - | - | - | - | - | - | - | ABL-301 | - | - | detail > | |
| Exidavnemab | Exidavnemab | Monoclonal antibody | Nervous System Diseases Endocrinology and Metabolic Disease Other Diseases | α-synuclein inhibitors | BioArctic AB | BioArctic AB | Phase 2 | - | - | - | - | Orphan Drug（European Union） Orphan Drug（United States） | - | - | - | - | Exidavnemab | - | - | detail > | |
| UB-312 | UB-312 | Synthetic peptide vaccine Therapeutic vaccine | Nervous System Diseases Endocrinology and Metabolic Disease Other Diseases | α-synuclein inhibitors | United Neuroscience Ltd. | Vaxxinity, Inc. NYU Langone Health | Phase 1/2 | - | - | - | - | Orphan Drug（European Union） | - | - | - | - | UB-312 | - | - | detail > | |
| ACI-12589 | ACI-12589 | Radiopharmaceuticals and diagnostic agent | Nervous System Diseases Endocrinology and Metabolic Disease Other Diseases | α-synuclein inhibitors | AC Immune SA | AC Immune SA | Phase 1 | - | - | - | - | - | - | - | - | - | ACI-12589 | - | - | detail > | |
| ASN-51 | ASN-51 | Small molecule drug | Nervous System Diseases Endocrinology and Metabolic Disease Other Diseases | Beta-N-acetylhexosaminidase inhibitors M1 receptor modulators α-synuclein modulators | Asceneuron SA | Asceneuron SA | Phase 1 | - | - | - | - | - | - | - | - | - | ASN-51 | - | - | detail > | |
| LY-3962681 | LY-3962681 | siRNA | Nervous System Diseases Endocrinology and Metabolic Disease | α-synuclein inhibitors | Prevail Therapeutics, Inc. | Prevail Therapeutics, Inc. | Phase 1 | - | - | - | - | - | - | - | - | - | LY-3962681 | - | - | detail > | |
| Ethambutol Hydrochloride/Rifampicin/Isoniazid | Ethambutol Hydrochloride/Rifampicin/Isoniazid | Small molecule drug | Infectious Diseases | Bacterial RNAP inhibitors α-synuclein inhibitors | Shenyang Hongqi Pharmaceutical Co., Ltd. | Shenyang Hongqi Pharmaceutical Co., Ltd. | Approved | Approved | China | 2008-03-03 | 2008-03-03 | - | - | - | - | - | Ethambutol Hydrochloride/Rifampicin/Isoniazid | - | - | detail > | |
| NPT-088 | NPT-088 | Fusion protein | Nervous System Diseases | APP inhibitors CD64 agonists PRNP inhibitors α-synuclein inhibitors Peptide aggregation inhibitors | Proclara Biosciences, Inc. | Proclara Biosciences, Inc. | Phase 1 | - | - | - | - | - | - | - | - | - | NPT-088 | - | - | detail > | |
| (-)-Epigallocatechin Gallate | (-)-Epigallocatechin Gallate | Small molecule drug | Nervous System Diseases Congenital Disorders Skin and Musculoskeletal Diseases Other Diseases Neoplasms Digestive System Disorders Immune System Diseases Infectious Diseases Cardiovascular Diseases Mouth and Tooth Diseases Respiratory Diseases | APP inhibitors DYRK1A inhibitors LOXL2 inhibitors α-synuclein inhibitors | Charité - Universitätsmedizin Berlin | Merdury Biopharmaceutical Corporation Zunyi Medical University The University of Texas Southwestern Medical Center Nanchang University Universidad de Guanajuato University of California, Los Angeles Pharmasset, Inc. Quanzhou Maternal and Child Health Hospital | Phase 3 | Preclinical | - | - | - | Orphan Drug（United States） | - | - | - | - | (-)-Epigallocatechin Gallate | - | - | detail > | |
| Braegen-05 | Braegen-05 | Small molecule drug | Nervous System Diseases Endocrinology and Metabolic Disease Other Diseases | α-synuclein modulators | Shenzhen Boruijian Pharmaceutical Co., Ltd. | Shenzhen Boruijian Pharmaceutical Co., Ltd. | Phase 1 | Phase 1 | - | - | - | - | - | - | - | - | Braegen-05 | - | - | detail > |
Total 174 data
1
2
3
4
5
6
...
17
18
